|
1
|
Sacuiu SF: Dementias. Handb Clin Neurol.
138:123–151. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Raz L, Knoefel J and Bhaskar K: The
neuropathology and cerebrovascular mechanisms of dementia. J Cereb
Blood Flow Metab. 36:172–186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Takeda S: Progression of Alzheimer's
disease, tau propagation, and its modifiable risk factors. Neurosci
Res. 141:36–42. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kertesz A: Frontotemporal dementia, Pick's
disease. Ideggyogy Sz. 63:4–12. 2010.PubMed/NCBI
|
|
5
|
Gomperts SN: Lewy body dementias: Dementia
with Lewy bodies and Parkinson disease Dementia. Continuum (Minneap
Minn). 22 (2 Dementia):435–463. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wachinger C, Salat DH, Weiner M and Reuter
M: Alzheimer's Disease Neuroimaging Initiative. Whole-brain
analysis reveals increased neuroanatomical asymmetries in dementia
for hippocampus and amygdala. Brain. 139:3253–3266. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Trifu S, Carp EG and Nadoleanu A: Alcohol
as a substitute, mask of depression and ‘antidote’ of narcissism.
Eur Proc Soc Behav Sci. 31:986–994. 2017.
|
|
8
|
Barker R, Ashby EL, Wellington D, Barrow
VM, Palmer JC, Kehoe PG, Esiri MM and Love S: Pathophysiology of
white matter perfusion in Alzheimer's disease and vascular
dementia. Brain. 137:1524–1532. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kolomiytsev AK and Bazilevich AV:
Morphologic changes in vascular dementia. Adv Stud Biol. 9:101–104.
2017.
|
|
10
|
Trifu SC, Tudor A and Radulescu I:
Aggressive behavior in psychiatric patients in relation to hormonal
imbalance (Review). Exp Ther Med. 20:3483–3487. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Weller RO, Hawkes CA, Kalaria RN, Werring
DJ and Carare RO: White matter changes in dementia: Role of
impaired drainage of interstitial fluid. Brain Pathol. 25:63–78.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kalaria RN: Small vessel disease and
Alzheimer's dementia: Pathological considerations. Cerebrovasc Dis.
13 (Suppl 2):S48–S52. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jellinger KA and Attems J:
Neuropathological evaluation of mixed dementia. J Neurol Sci.
257:80–87. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dragoi AM, Radulescu I, Năsui BA, Pop AL,
Varlas VN and Trifu S: Clozapine: An updated overview of
pharmacogenetic biomarkers, risks, and safety-particularities in
the context of COVID-19. Brain Sci. 10(840)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Johnson GV and Stoothoff WH: Tau
phosphorylation in neuronal cell function and dysfunction. J Cell
Sci. 117:5721–5729. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Silva MC and Haggarty SJ: Tauopathies:
Deciphering disease mechanisms to develop effective therapies. Int
J Mol Sci. 21(8948)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kalaria RN, Kenny RA, Ballard CG, Perry R,
Ince P and Polvikoski T: Towards defining the neuropathological
substrates of vascular dementia. J Neurol Sci. 226:75–80.
2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bondy SC: Low levels of aluminum can lead
to behavioral and morphological changes associated with Alzheimer's
disease and age-related neurodegeneration. Neurotoxicology.
52:222–229. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schneider JA, Arvanitakis Z, Bang W and
Bennett DA: Mixed brain pathologies account for most dementia cases
in community-dwelling older persons. Neurology. 69:2197–2204.
2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
O'Brien JT and Thomas A: Vascular
dementia. Lancet. 386:1698–1706. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jagust WJ, Zheng L, Harvey DJ, Mack WJ,
Vinters HV, Weiner MW, Ellis WG, Zarow C, Mungas D, Reed BR, et al:
Neuropathological basis of magnetic resonance images in aging and
dementia. Ann Neurol. 63:72–80. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schneider JA, Wilson RS, Bienias JL, Evans
DA and Bennett DA: Cerebral infarctions and the likelihood of
dementia from Alzheimer disease pathology. Neurology. 62:1148–1155.
2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Laforce R Jr and Rabinovici GD: Amyloid
imaging in the differential diagnosis of dementia: Review and
potential clinical applications. Alzheimers Res Ther.
3(31)2011.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Jack CR Jr, Petersen RC, Xu Y, O'Brien PC,
Smith GE, Ivnik RJ, Boeve BF, Tangalos EG and Kokmen E: Rates of
hippocampal atrophy correlate with change in clinical status in
aging and AD. Neurology. 55:484–489. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Edwards-Lee T, Miller BL, Benson DF,
Cummings JL, Russell GL, Boone K and Mena I: The temporal variant
of frontotemporal dementia. Brain. 120:1027–1040. 1997.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Palesi F, De Rinaldis A, Vitali P,
Castellazzi G, Casiraghi L, Germani G, Bernini S, Anzalone N,
Ramusino MC, Denaro FM, et al: Specific patterns of white matter
alterations help distinguishing Alzheimer's and vascular dementia.
Front Neurosci. 12(274)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hshieh TT, Fong TG, Marcantonio ER and
Inouye SK: Cholinergic deficiency hypothesis in delirium: A
synthesis of current evidence. J Gerontol A Biol Sci Med Sci.
63:764–772. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Revett TJ, Baker GB, Jhamandas J and Kar
S: Glutamate system, amyloid β peptides and tau protein: Functional
interrelationships and relevance to Alzheimer disease pathology. J
Psychiatry Neurosci. 38:6–23. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Grossberg GT: Cholinesterase inhibitors
for the treatment of Alzheimer's disease: Getting on and staying
on. Curr Ther Res Clin Exp. 64:216–235. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
van Laar T, De Deyn PP, Aarsland D, Barone
P and Galvin JE: Effects of cholinesterase inhibitors in
Parkinson's disease dementia: A review of clinical data. CNS
Neurosci Ther. 17:428–441. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dyer SM, Laver K, Pond CD, Cumming RG,
Whitehead C and Crotty M: Clinical practice guidelines and
principles of care for people with dementia in Australia. Aust Fam
Physician. 45:884–889. 2016.PubMed/NCBI
|
|
32
|
Gauthier S, Patterson C, Chertkow H,
Gordon M, Herrmann N, Rockwood K, Rosa-Neto P and Soucy JP: CCCDTD4
participants. 4th canadian consensus conference on the diagnosis
and treatment of dementia. Can J Neurol Sci. 39 (Suppl 5):S1–S8.
2012.PubMed/NCBI View Article : Google Scholar : (In English,
French).
|
|
33
|
Colović MB, Krstić DZ, Lazarević-Pašti TD,
Bondžić AM and Vasić VM: Acetylcholinesterase inhibitors:
Pharmacology and toxicology. Curr Neuropharmacol. 11:315–335.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
McShane R, Westby MJ, Roberts E, Minakaran
N, Schneider L, Farrimond LE, Maayan N, Ware J and Debarros J:
Memantine for dementia. Cochrane Database Syst Rev.
3(CD003154)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Overshott R and Burns A: Treatment of
dementia. J Neurol Neurosurg Psychiatry. 76 (Suppl 5):v53–v59.
2005.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Schneider LS, Mangialasche F, Andreasen N,
Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L,
Winblad B and Kivipelto M: Clinical trials and late-stage drug
development for Alzheimer's disease: An appraisal from 1984 to
2014. J Intern Med. 275:251–283. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lilienfeld S: Galantamine-a novel
cholinergic drug with a unique dual mode of action for the
treatment of patients with Alzheimer's disease. CNS Drug Rev.
8:159–176. 2002.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hashiguchi M, Ohta Y, Shimizu M, Maruyama
J and Mochizuki M: Meta-analysis of the efficacy and safety of
Ginkgo biloba extract for the treatment of dementia. J Pharm
Health Care Sci. 1(14)2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Benito-León J, Contador I, Vega S,
Villarejo-Galende A and Bermejo-Pareja F: Non-steroidal
anti-inflammatory drugs use in older adults decreases risk of
Alzheimer's disease mortality. PLoS One.
14(e0222505)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Farina N, Llewellyn D, Isaac MG and Tabet
N: Vitamin E for Alzheimer's dementia and mild cognitive
impairment. Cochrane Database Syst Rev. 1(CD002854)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Walker Z, Possin KL, Boeve BF and Aarsland
D: Lewy body dementias. Lancet. 386:1683–1697. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Travagli RA, Browning KN and Camilleri M:
Parkinson disease and the gut: New insights into pathogenesis and
clinical relevance. Nat Rev Gastroenterol Hepatol. 17:673–685.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Trist BG, Hare DJ and Double KL: Oxidative
stress in the aging substantia nigra and the etiology of
Parkinson's disease. Aging Cell. 18(e13031)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rockenstein E, Nuber S, Overk CR, Ubhi K,
Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P,
et al: Accumulation of oligomer-prone α-synuclein exacerbates
synaptic and neuronal degeneration in vivo. Brain. 137:1496–1513.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Stefanis L: α-Synuclein in Parkinson's
disease. Cold Spring Harb Perspect Med. 2(a009399)2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Meireles J and Massano J: Cognitive
impairment and dementia in Parkinson's disease: Clinical features,
diagnosis, and management. Front Neurol. 3(88)2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jung I and Kim JS: Abnormal eye movements
in parkinsonism and movement disorders. J Mov Disord. 12:1–13.
2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wichniak A, Wierzbicka A, Walęcka M and
Jernajczyk W: Effects of antidepressants on sleep. Curr Psychiatry
Rep. 19(63)2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Martilla RJ and Rinne UK: Dementia in
Parkinson's disease. Arch Neurol Scand. 54:431–441. 1976.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Behari M, Bhattacharyya KB, Borgohain R,
Das SK, Ghosh B, Kishore A, Krishnan S, Mridula KR, Muthane U, Pal
PK, et al: Parkinson's disease. Ann Indian Acad Neurol. 14 (Suppl
1):S2–S6. 2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mitchell CT, Krier I, Arjomand J, Borowsky
B, Tabrizi SJ and Leavitt BR: TRACK-HD Investigators Luthi-Carter
R. Longitudinal expression changes are weak correlates of disease
progression in Huntington's disease. Brain Commun.
2(fcaa172)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Potkin KT and Potkin SG: New directions in
therapeutics for Huntington disease. Future Neurol. 13:101–121.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Pla P, Orvoen S, Saudou F, David DJ and
Humbert S: Mood disorders in Huntington's disease: From behavior to
cellular and molecular mechanisms. Front Behav Neurosci.
8(135)2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Butters N, Wolfe J, Granholm E and Martone
M: An assessment of verbal recall, recognition and fluency
abilities in patients with Huntington's disease. Cortex. 22:11–32.
1986.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Rohrer D, Salmon DP, Wixted JT and Paulsen
JS: The disparate effects of Alzheimer's disease and Huntington's
disease on semantic memory. Neuropsychology. 13:381–388.
1999.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Setti SE, Hunsberger HC and Reed MN:
Alterations in hippocampal activity and Alzheimer's disease. Transl
Issues Psychol Sci. 3:348–356. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Dalton MA, Zeidman P, Barry DN, Williams E
and Maguire EA: Segmenting subregions of the human hippocampus on
structural magnetic resonance image scans: An illustrated tutorial.
Brain Neurosci Adv. 1(2398212817701448)2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Vyas Y, Montgomery JM and Cheyne JE:
Hippocampal deficits in amyloid-β-related rodent models of
Alzheimer's disease. Front Neurosci. 14(266)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
deToledo-Morrell L, Stoub TR, Bulgakova M,
Wilson RS, Bennett DA, Leurgans S, Wuu J and Turner DA: MRI-derived
entorhinal volume is a good predictor of conversion from MCI to AD.
Neurobiol Aging. 25:1197–1203. 2004.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Köhler C: Granulovacuolar degeneration: A
neurodegenerative change that accompanies tau pathology. Acta
Neuropathol. 132:339–359. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mitake S, Ojika K and Hirano A: Hirano
bodies and Alzheimer's disease. Kaohsiung J Med Sci. 13:10–18.
1997.PubMed/NCBI
|
|
62
|
Connor B, Beilharz EJ, Williams C, Synek
B, Gluckman PD, Faull RL and Dragunow M: Insulin-like growth
factor-I (IGF-I) immunoreactivity in the Alzheimer's disease
temporal cortex and hippocampus. Brain Res Mol Brain Res.
49:283–290. 1997.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Connor B, Young D, Yan Q, Faull RL, Synek
B and Dragunow M: Brain-derived neurotrophic factor is reduced in
Alzheimer's disease. Brain Res Mol Brain Res. 49:71–81.
1997.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Griffith CM, Eid T, Rose GM and Patrylo
PR: Evidence for altered insulin receptor signaling in Alzheimer's
disease. Neuropharmacology. 136:202–215. 2018.PubMed/NCBI View Article : Google Scholar
|
